{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
US Approved Rx
(2017)
Source:
BLA761060
(2017)
Source URL:
First approved in 2000
Source:
Mylotarg
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2000)
Source:
BLA020986
(2000)
Source URL:
First approved in 2000
Source:
BLA020986
Source URL:
Class:
PROTEIN
Targets:
Conditions:
Insulin aspart, a human insulin analogue, is a rapid-acting, parenteral blood glucose-lowering agent. Insulin aspart was marketed under the brand name NovoLog for the treatment of adult patients with diabetes mellitus, for the control of hyperglycemia. The primary activity of the drug is the regulation of glucose metabolism. Insulin aspart binds to the insulin receptors on muscle and fat cells and lower blood glucose by facilitating the cellular uptake of glucose and simultaneously inhibiting the output of glucose from the liver. This drug has an off-label treatment for gestational diabetes (temporary diabetes caused by diabetes).
Status:
US Approved Rx
(2015)
Source:
BLA205692
(2015)
Source URL:
First approved in 2000
Source:
BLA021081
Source URL:
Class:
PROTEIN
Targets:
Insulin glargine, a long-acting form of insulin, was marketed under the brand name LANTUS. Lantus is indicated for the treatment of adult and pediatric patients with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia. The primary activity of insulin glargine is regulation of glucose metabolism. It lowers blood glucose levels by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. The off-label use of insulin glargine is the treatment type 2 diabetes in children and the treatment of gestational diabetes.
Status:
US Approved Rx
(2000)
Source:
BLA103909
(2000)
Source URL:
First approved in 2000
Source:
BLA103909
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2000)
Source:
NDA020715
(2000)
Source URL:
First approved in 2000
Source:
NDA020715
Source URL:
Class:
PROTEIN
Conditions:
Triptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). It works by decreasing the production of certain hormones, which reduces testosterone levels in the body. Animal studies comparing triptorelin to native GnRH found that triptorelin had 13 fold higher releasing activity for luteinizing hormone, and 21-fold higher releasing activity for follicle-stimulating hormone. Triptorelin is indicated for the palliative treatment of advanced prostate cancer.
Status:
US Approved Rx
(2000)
Source:
BLA103846
(2000)
Source URL:
First approved in 2000
Source:
BLA103846
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(1999)
Source:
BLA103767
(1999)
Source URL:
First approved in 1999
Source:
BLA103767
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2019)
Source:
BLA761086
(2019)
Source URL:
First approved in 1998
Source:
BLA103772
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(1998)
Source:
BLA103770
(1998)
Source URL:
First approved in 1998
Source:
BLA103770
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(1998)
Source:
BLA020772
(1998)
Source URL:
First approved in 1998
Source:
BLA020772
Source URL:
Class:
PROTEIN